Based on the Sana Biotechnology Inc stock forecast from 3 analysts, the average analyst target price for Sana Biotechnology Inc is USD 9.80 over the next 12 months. Sana Biotechnology Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Sana Biotechnology Inc is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, Sana Biotechnology Inc’s stock price was USD 1.76. Sana Biotechnology Inc’s stock price has changed by +18.92% over the past week, -39.73% over the past month and -80.36% over the last year.
Past 12 monthsNext 12 months
No recent analyst target price found for Sana Biotechnology Inc
No recent average analyst rating found for Sana Biotechnology Inc
Company Overview Sana Biotechnology Inc
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington. Read Less
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorde...Read More
Frequently Asked Questions About Sana Biotechnology Inc (SANA) Stock
Based on ratings from 3 analysts Sana Biotechnology Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 5 buy, sell and hold ratings.
Unfortunately we do not have enough data on SANA's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for SANA is USD 9.80 over the next 12 months. The maximum analyst target price is USD 12 while the minimum anlayst target price is USD 7.
Unfortunately we do not have enough data on SANA's stock to indicate if its overvalued.
The last closing price of SANA's stock was USD 1.76.
The most recent market capitalization for SANA is USD 0.61B.
Based on targets from 3 analysts, the average taret price for SANA is projected at USD 9.80 over the next 12 months.
This means that SANA's stock price may go up by +456.82% over the next 12 months.
We can't find any ETFs which contains Sana Biotechnology Inc's stock.
As per our most recent records Sana Biotechnology Inc has 328 Employees.
Sana Biotechnology Inc's registered address is 188 East Blaine Street, Seattle, WA, United States, 98102.
You can get more information about it from Sana Biotechnology Inc's website at https://www.sana.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Sana Biotechnology Inc (SANA) Stock
Based on ratings from 3 analysts Sana Biotechnology Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 5 buy, sell and hold ratings.
Unfortunately we do not have enough data on SANA's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for SANA is USD 9.80 over the next 12 months. The maximum analyst target price is USD 12 while the minimum anlayst target price is USD 7.
Unfortunately we do not have enough data on SANA's stock to indicate if its overvalued.
The last closing price of SANA's stock was USD 1.76.
The most recent market capitalization for SANA is USD 0.61B.
Based on targets from 3 analysts, the average taret price for SANA is projected at USD 9.80 over the next 12 months.
This means that SANA's stock price may go up by +456.82% over the next 12 months.
We can't find any ETFs which contains Sana Biotechnology Inc's stock.
As per our most recent records Sana Biotechnology Inc has 328 Employees.
Sana Biotechnology Inc's registered address is 188 East Blaine Street, Seattle, WA, United States, 98102.
You can get more information about it from Sana Biotechnology Inc's website at https://www.sana.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SANA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
